Home > Publications Database > Training with Odors Impacts Hippocampal Thickness in Patients with Mild Cognitive Impairment > print |
001 | 164663 | ||
005 | 20240320104852.0 | ||
024 | 7 | _ | |a 10.3233/JAD-220248 |2 doi |
024 | 7 | _ | |a 1387-2877 |2 ISSN |
024 | 7 | _ | |a 1875-8908 |2 ISSN |
024 | 7 | _ | |a altmetric:129766101 |2 altmetric |
024 | 7 | _ | |a pmid:35694924 |2 pmid |
037 | _ | _ | |a DZNE-2022-01193 |
041 | _ | _ | |a English |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Haehner, Antje |b 0 |
245 | _ | _ | |a Training with Odors Impacts Hippocampal Thickness in Patients with Mild Cognitive Impairment |
260 | _ | _ | |a Amsterdam |c 2022 |b IOS Press |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1710928088_2066 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a The olfactory system is affected early in Alzheimer’s disease and olfactory loss can already be observed in patients with mild cognitive impairment (MCI). Olfactory training is effective for improving olfactory and cognitive function by stimulating the olfactory pathway, but its effect on patients with MCI remains unclear.Objective:The aim of this randomized, prospective, controlled, blinded study was to assess whether a 4-month period of olfactory training (frequent short-term sniffing various odors) may have an effect on olfactory function, cognitive function, and morphology of medial temporal lobe (MTL) subregions and olfactory bulb in MCI patients.Methods:A total of thirty-seven MCI patients were randomly assigned to the training group or a placebo group, which were performed twice a day for 4 months. Olfactory assessments, cognitive tests and magnetic resonance imaging were performed at the baseline and follow-up period.Results:After the training, there was an increase in odor discrimination, and increased cortical thickness of bilateral hippocampus (CA23DG and CA1) and mean MTL. Additionally, the change of olfactory score was positively associated with change of volume of olfactory bulb and hippocampus; the change of global cognition was positively associated with change of cortical thickness of hippocampus, entorhinal cortex and mean MTL; the change of cortical thickness of entorhinal cortex was positively associated with change of executive function.Conclusion:Olfactory training was associated with an increase in cortical thickness of the hippocampus but not olfactory bulb volume in patients with MCI. Olfactory training may serve as an early intervention of preventing hippocampal atrophy. |
536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, Journals: pub.dzne.de |
650 | _ | 7 | |a Cortical thickness |2 Other |
650 | _ | 7 | |a hippocampus |2 Other |
650 | _ | 7 | |a mild cognitive impairment |2 Other |
650 | _ | 7 | |a olfactory bulb |2 Other |
650 | _ | 7 | |a olfactory training |2 Other |
650 | _ | 2 | |a Alzheimer Disease: pathology |2 MeSH |
650 | _ | 2 | |a Cognitive Dysfunction: diagnostic imaging |2 MeSH |
650 | _ | 2 | |a Cognitive Dysfunction: pathology |2 MeSH |
650 | _ | 2 | |a Cognitive Dysfunction: therapy |2 MeSH |
650 | _ | 2 | |a Entorhinal Cortex: pathology |2 MeSH |
650 | _ | 2 | |a Hippocampus: pathology |2 MeSH |
650 | _ | 2 | |a Humans |2 MeSH |
650 | _ | 2 | |a Magnetic Resonance Imaging: methods |2 MeSH |
650 | _ | 2 | |a Odorants |2 MeSH |
650 | _ | 2 | |a Prospective Studies |2 MeSH |
700 | 1 | _ | |a Chen, Ben |b 1 |
700 | 1 | _ | |a Espin, Melanie |b 2 |
700 | 1 | _ | |a Haussmann, Robert |0 P:(DE-2719)9000458 |b 3 |u dzne |
700 | 1 | _ | |a Matthes, Claudia |b 4 |
700 | 1 | _ | |a Desser, Dmitriy |b 5 |
700 | 1 | _ | |a Loessner, Lorenz |b 6 |
700 | 1 | _ | |a Brandt, Moritz D. |0 P:(DE-2719)2812107 |b 7 |u dzne |
700 | 1 | _ | |a Donix, Markus |0 P:(DE-2719)2501739 |b 8 |u dzne |
700 | 1 | _ | |a Hummel, Thomas |b 9 |
773 | _ | _ | |a 10.3233/JAD-220248 |g p. 1 - 13 |0 PERI:(DE-600)2070772-1 |n 2 |p 743-755 |t Journal of Alzheimer's disease |v 88 |y 2022 |x 1387-2877 |
856 | 4 | _ | |u https://pub.dzne.de/record/164663/files/DZNE-2022-01193_Restricted.pdf |
856 | 4 | _ | |u https://pub.dzne.de/record/164663/files/DZNE-2022-01193_Restricted.pdf?subformat=pdfa |x pdfa |
909 | C | O | |p VDB |o oai:pub.dzne.de:164663 |
910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 3 |6 P:(DE-2719)9000458 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)2812107 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 8 |6 P:(DE-2719)2501739 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
914 | 1 | _ | |y 2022 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-04 |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-04 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-18 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-18 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-18 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-18 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-18 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J ALZHEIMERS DIS : 2021 |d 2022-11-18 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-18 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-18 |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-18 |
915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-18 |
920 | 1 | _ | |0 I:(DE-2719)1710008 |k AG Donix |l Clinical Planning and Intersite Group |x 0 |
920 | 1 | _ | |0 I:(DE-2719)1710012 |k AG Falkenburger |l Translational Parkinson Research |x 1 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-2719)1710008 |
980 | _ | _ | |a I:(DE-2719)1710012 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|